Literature DB >> 19960483

A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management.

Liana Martirosyan1, Jaco Voorham, Flora M Haaijer-Ruskamp, Jozé Braspenning, Bruce H R Wolffenbuttel, Petra Denig.   

Abstract

PURPOSE: Valid prescribing indicators (PI) are needed for reliable assessment of prescribing quality. The purpose of this study is to describe the validity of existing PI for type 2 diabetes mellitus and cardiovascular risk management.
METHODS: We conducted a systematic literature search for studies describing the development and assessment of relevant PIs between January 1990 and January 2009. We grouped identified PI as drug- or disease-oriented, and according to the aspects of prescribing addressed and the additional clinical information included. We reviewed the clinimetric characteristics of the different types of PI.
RESULTS: We identified 59 documents describing the clinimetrics of 16 types of PI covering relevant prescribing aspects, including first-choice treatment, safety issues, dosing, costs, sufficient and timely treatment. We identified three types of drug-oriented, and five types of disease-oriented PI with proven face and content validity as well as operational feasibility in different settings. PI focusing on treatment modifications were the only indicators that showed concurrent validity. Several solutions were proposed for dealing with case-mix and sample size problems, but their actual effect on PI scores was insufficiently assessed. Predictive validity of individual PI is not yet known.
CONCLUSION: We identified a range of existing PI that are valid for internal quality assessment as they are evidence-based, accepted by professionals, and reliable. For external use, problems of patient case-mix and sample size per PI should be better addressed. Further research is needed for selecting indicators that predict clinical outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 19960483     DOI: 10.1002/pds.1894

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  8 in total

1.  Do we need individualised prescribing quality assessment? The case of diabetes treatment.

Authors:  Petra Denig; Flora Haaijer-Ruskamp
Journal:  Int J Clin Pharm       Date:  2011-04

2.  A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators.

Authors:  Liana Martirosyan; Joekie Markhorst; Petra Denig; Flora M Haaijer-Ruskamp; Jozé Braspenning
Journal:  BMC Health Serv Res       Date:  2012-07-07       Impact factor: 2.655

3.  A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness.

Authors:  Grigory Sidorenkov; Flora M Haaijer-Ruskamp; Dick de Zeeuw; Petra Denig
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

4.  Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement.

Authors:  Tobias Dreischulte; Aileen M Grant; Colin McCowan; John J McAnaw; Bruce Guthrie
Journal:  BMC Clin Pharmacol       Date:  2012-02-08

5.  Role of Pharmacovigilance in India: An overview.

Authors:  Sanvidhan G Suke; Prabhat Kosta; Harsh Negi
Journal:  Online J Public Health Inform       Date:  2015-07-01

6.  Evaluating medication-related quality of care in residential aged care: a systematic review.

Authors:  Jodie B Hillen; Agnes Vitry; Gillian E Caughey
Journal:  Springerplus       Date:  2015-05-14

7.  Primary health care quality indicators: An umbrella review.

Authors:  André Ramalho; Pedro Castro; Manuel Gonçalves-Pinho; Juliana Teixeira; João Vasco Santos; João Viana; Mariana Lobo; Paulo Santos; Alberto Freitas
Journal:  PLoS One       Date:  2019-08-16       Impact factor: 3.240

8.  Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness method.

Authors:  Benjamin Joseph Basger; Timothy Frank Chen; Rebekah Jane Moles
Journal:  BMJ Open       Date:  2012-09-14       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.